Ascelia is an oncology-dedicated pharma company, based in Malmö, Sweden, that develops novel pharmaceutical products aimed to improve the life expectancy and quality of life for people living with cancer. 

Ascelia’s core focus is development and commercialization of its current portfolio of differentiated, underappreciated and de-risked product candidates addressing unmet medical needs in cancer and cancer-related diseases.

Ascelia has two clinical stage product candidates under development: lead candidate Mangoral, which is an imaging drug for detection and localization of liver metastases in patients where use of gadolinium based contrast may be medically inadvisable and Oncoral, which is a novel tablet formulation of the well-known chemotherapeutic agent, Irinotecan.

For more information, please contact:

Søren Lemonius

Managing General Partner

Phone: +45 2270 5065